血浆MIA、CRP和白蛋白预测帕金森病认知功能下降
研究采用多队列发现-复制-验证设计,在发现队列108例和复制队列83例帕金森病患者中检测940种血浆蛋白,构建包含MIA、CRP和白蛋白的3蛋白逻辑回归模型预测快速认知下降,在验证队列118例中AUC为0.80,风险最高四分位者发生轻度认知障碍或痴呆的风险是最低四分位的4.4倍,MIA单核苷酸多态性rs2233154与MIA水平及认知下降相关。
要点
- 3蛋白模型(MIA、CRP、白蛋白)在验证队列中区分快速与慢速认知下降的AUC为0.80。
- 验证队列中风险最高四分位者发生轻度认知障碍或痴呆的风险是最低四分位的4.4倍。
- MIA单核苷酸多态性rs2233154与MIA水平及认知下降相关,提示MIA可能参与认知下降的因果过程。
核心结论
- 基于血浆的预测模型可识别有认知下降风险的帕金森病患者,MIA可能因果性参与认知下降的发生。
研究设计与样本
- 多队列发现-复制-验证设计,发现队列108例帕金森病患者,复制队列83例,验证队列118例。
- 在发现和复制队列中使用基于适配体的平台检测940种血浆蛋白。
主要发现
- 仅含MIA、CRP和白蛋白3种蛋白的模型在验证队列中区分快速与慢速认知下降的AUC为0.80。
- 验证队列中基于该模型认知下降风险最高四分位的帕金森病患者发生轻度认知障碍或痴呆的风险是最低四分位的4.4倍。
- MIA单核苷酸多态性rs2233154与MIA水平及认知下降相关,为MIA的因果影响提供证据。
关键数值与推荐
- 快速认知下降定义为蒙特利尔认知评估(MoCA)每年下降≥1分,慢速认知下降定义为每年下降<1分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Using a multi-cohort, discovery-replication-validation design, we sought new plasma biomarkers that predict which individuals with Parkinson's disease (PD) will experience cognitive decline. METHODS: In 108 discovery cohort PD individuals and 83 replication cohort PD individuals, we measured 940 plasma proteins on an aptamer-based platform. Using proteins associated with subsequent cognitive decline in both cohorts, we trained a logistic regression model to predict which patients with PD showed fast (> = 1 point drop/year on Montreal Cognitive Assessment [MoCA]) versus slow (< 1 point drop/year on MoCA) cognitive decline in the discovery cohort, testing it in the replication cohort. We developed alternate assays for the top 3 proteins and confirmed their ability to predict cognitive decline - defined by change in MoCA or development of incident mild cognitive impairment (MCI) or dementia - in a validation cohort of 118 individuals with PD. We investigated the top plasma biomarker for causal influence by Mendelian randomization (MR). RESULTS: A model with only 3 proteins (melanoma inhibitory activity protein [MIA], C-reactive protein [CRP], and albumin) separated fast versus slow cognitive decline subgroups with an area under the curve (AUC) of 0.80 in the validation cohort. The individuals with PD in the validation cohort in the top quartile of risk for cognitive decline based on this model were 4.4 times more likely to develop incident MCI or dementia than those in the lowest quartile. Genotypes at MIA single nucleotide polymorphism (SNP) rs2233154 associated with MIA levels and cognitive decline, providing evidence for MIA's causal influence. CONCLUSIONS: An easily obtained plasma-based predictor identifies individuals with PD at risk for cognitive decline. MIA may participate causally in development of cognitive decline. ANN NEUROL 2022;92:255-269.
引用
- Shen J, Amari N, Zack R, et al. Plasma MIA, CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease. Ann Neurol. 2022. PMID: 35593028. doi:10.1002/ana.26410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。